We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
GlaxoSmithKline plc is a drug manufacturers-general business with stocks listed in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$45.1 – a decrease of 0.81% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$32.2627 - US$45.67 |
|---|---|
| 50-day moving average | US$43.0594 |
| 200-day moving average | US$40.3222 |
| Target price | US$46.27 |
| PE ratio | 19.4482 |
| Dividend yield | US$0.8 (4.83%) |
| Earnings per share (TTM) | US$2.338 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $45.1
| 1 week (2022-01-13) | 0.09% |
|---|---|
| 1 month (2021-12-23) | 3.06% |
| 3 months (2021-10-22) | 13.40% |
| 6 months (2021-07-23) | 14.15% |
| 1 year (2021-01-22) | 17.57% |
|---|---|
| 2 years (2020-01-23) | -5.69% |
| 3 years (2019-01-23) | 15.43% |
| 5 years (2017-01-23) | 15.88% |
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, GlaxoSmithKline shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.6624. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$10.2 billion (£7.5 billion).
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$33.3 billion |
|---|---|
| Operating margin TTM | 24.78% |
| Gross profit TTM | US$23.2 billion |
| Return on assets TTM | 6.47% |
| Return on equity TTM | 23.62% |
| Profit margin | 12.94% |
| Book value | 6.16 |
| Market capitalisation | US$114.4 billion |
TTM: trailing 12 months
Dividend payout ratio: 72.16% of net profits
Recently GlaxoSmithKline has paid out, on average, around 72.16% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 4.83% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.8 per share.
GlaxoSmithKline's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
GlaxoSmithKline's most recent dividend payout was on 12 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 17 November 2021 (the "ex-dividend date").
GlaxoSmithKline's shares were split on a 2:1 basis on 11 November 1991. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as US$32.2627 up to US$45.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.3829. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Which one protects you best, and where can you buy them online?
Here’s what Ryan Edwards-Pritchard learned so far about building a startup in the grips of a pandemic.
Arsenal and Liverpool are locked at 0-0 ahead of their Carabao Cup semi-final second leg this week.
Heres how stock levels and prices are holding up for RATs in Australia.
Learn how to stake OHM and receive high yield from one of DeFi's most ambitious experiments.
Being early to a new DeFi ecosystem can be very profitable – here's how to game the system and potentially earn yourself some tokens.
Reporting season is a 2-week or so period where investors can see the results for a large number of publicly traded companies.
Bank First’s variable rate green personal loan can be used to make environmentally friendly purchases for your home.
The 10 biggest movers on the ASX for Thursday 20 January 2022.
